{"filing":{"accession_number":"0001193125-26-428306","cik":"0001703647","ticker":"KRRO","company_name":"Korro Bio, Inc.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"krro-20261022.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526428306/krro-20261022.htm"},"events":[{"id":37021,"run_id":34122,"accession_number":"0001193125-26-428306","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Korro Bio disclosed preclinical results for KRRO-111, its development candidate for Alpha-1 Antitrypsin Deficiency, demonstrating \u003e95% SERPINA1 mRNA editing and sustained restoration of functional M-AAT in repeat-dose studies. The company announced a regulatory submission expected in the first half of 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company advancing a pipeline program, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. The disclosure would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory pathway.","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41601,"accession_number":"0001193125-26-428306","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Korro Bio disclosed preclinical results for KRRO-111, its development candidate for Alpha-1 Antitrypsin Deficiency, demonstrating \u003e95% SERPINA1 mRNA editing and sustained restoration of functional M-AAT in repeat-dose studies. The company announced a regulatory submission expected in the first half of 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company advancing a pipeline program, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. The disclosure would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:05:49.579925+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41601,"accession_number":"0001193125-26-428306","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Korro Bio disclosed preclinical results for KRRO-111, its development candidate for Alpha-1 Antitrypsin Deficiency, demonstrating \u003e95% SERPINA1 mRNA editing and sustained restoration of functional M-AAT in repeat-dose studies. The company announced a regulatory submission expected in the first half of 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company advancing a pipeline program, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. The disclosure would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:05:49.579925+00:00","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-10-22"}]}